Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.

Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q34200875

about

Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines The study of a novel sorafenib derivative HLC-080 as an antitumor agent Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.Melittin restores PTEN expression by down-regulating HDAC2 in human hepatocelluar carcinoma HepG2 cells.OIP5, a target of miR-15b-5p, regulates hepatocellular carcinoma growth and metastasis through the AKT/mTORC1 and β-catenin signaling pathways.Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance.Silencing alpha-fetoprotein inhibits VEGF and MMP-2/9 production in human hepatocellular carcinoma cell.The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206 PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma p-21-Activated kinase 1 mediates gastrin-stimulated proliferation in the colorectal mucosa via multiple signaling pathways.Modification of sialylation mediates the invasive properties and chemosensitivity of human hepatocellular carcinoma.IRE1α-XBP1 pathway promotes melanoma progression by regulating IL-6/STAT3 signaling.Therapeutic target database update 2014: a resource for targeted therapeutics.Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.Insulin/Insulin-Like Growth Factor-1 Pathway in Barrett's Carcinogenesis Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines Overexpression of fibrinogen-like protein 2 induces epithelial-to-mesenchymal transition and promotes tumor progression in colorectal carcinoma.Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3.Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma.

P2860

Q21245750-8969D552-30B2-4E91-A4FF-47091E1545E7 Q28485293-95F17614-983E-4609-A366-D0E19F7A8A09 Q28540521-9EAE32F6-9DFE-4CF7-8C69-8DA57E8E0C84 Q33406591-1DF59A84-264F-451B-B469-F2EE680A6C6C Q33408291-8FF941AE-534F-4A9D-965C-0E6CE7A5ECC2 Q33559887-9C61C593-809F-4147-9B70-C5287C847900 Q33566841-ADC91E14-2406-4E9B-A88F-5EA162057C02 Q34466060-94052B3A-16C1-41A0-817E-7F5ECF46A95A Q35109163-641B7480-E6B5-4FB4-B824-8B5CFAA73844 Q35546455-B26BFB19-30E6-406B-A7E7-BE292A8D9E58 Q36204986-765737FD-D65E-4449-92DC-17CA3243CAA8 Q36699721-8276C041-949A-4E1C-9247-8431F38AF546 Q37563910-A85A658E-80C9-438D-BC50-6E57F83D68D5 Q37658270-8C8891E9-32A5-4759-9EFF-90CFCBF1ECBC Q37661746-38944519-C56A-46E1-85DF-97C2C287848E Q37671148-E9BD3A6A-F87A-424A-AFB1-1DF54E898794 Q39561604-AF92C32F-6A56-43AF-81AE-8FDA52C600D8 Q41969486-80C3C0B6-AD7C-40BA-937C-7ECA9CB53B5D Q44185778-2F98934E-F661-425C-A81F-996B7070B93C Q51323736-306E3621-6B14-4674-B4D9-8C584033CCB1 Q55269976-95725DBF-6C99-49D0-8815-4FDB8312F671

P2860

Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.

http://www.wikidata.org/entity/Q34200875

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Activation of PI3K/AKT and MAP ...... e in hepatocellular carcinoma.

@ast

Activation of PI3K/AKT and MAP ...... e in hepatocellular carcinoma.

@en

Activation of PI3K/AKT and MAP ...... e in hepatocellular carcinoma.

@nl

type

label

Activation of PI3K/AKT and MAP ...... e in hepatocellular carcinoma.

@ast

Activation of PI3K/AKT and MAP ...... e in hepatocellular carcinoma.

@en

Activation of PI3K/AKT and MAP ...... e in hepatocellular carcinoma.

@nl

prefLabel

Activation of PI3K/AKT and MAP ...... e in hepatocellular carcinoma.

@ast

Activation of PI3K/AKT and MAP ...... e in hepatocellular carcinoma.

@en

Activation of PI3K/AKT and MAP ...... e in hepatocellular carcinoma.

@nl

P1433

Q34200875-57C2CE37-233B-45C0-856C-ACE9C8B0F93A

P1476

Q34200875-31794FBB-70C3-46F2-BED7-597736896C72

P2093

Q34200875-14797079-8846-4970-8533-75EBCA822449

Q34200875-68CF7E47-574B-48F8-8DCF-AB0011F7DD00

Q34200875-8A1BD9AF-AF50-4589-A378-47220AD6876C

Q34200875-8B82BC59-A01B-4679-8729-531EC5420E87

Q34200875-AAB8378F-6BCB-4BE4-9A5A-C07F640E3170

Q34200875-AC62C334-3D75-4432-9802-F80804DF05F3

Q34200875-B0B34C02-018C-408B-98DD-C41FAA6BCB54

Q34200875-BEE5D88D-DCB4-4668-8B9B-55B6C6243AA3

Q34200875-C7BB0597-7D3E-4574-97D0-A846C2A32D40

Q34200875-E835CD7A-95EC-4046-93CA-FF3BE38E6034

P2860

Q34200875-01698A76-D819-4EE1-82F4-BBEF9B6A1B5F

Q34200875-028F1D7F-6C2E-4C7B-A115-01237A65CE07

Q34200875-03B961F7-144C-406B-A9D6-27CC805D8CCD

Q34200875-0C9101BB-19F2-4931-ACF5-8F2BD92B0CE8

Q34200875-19139FB6-69C5-4BD5-A589-F46645305E35

Q34200875-29A5EF45-908D-4CA3-A757-DFE474432991

Q34200875-2A3771F4-6C53-4F58-BA6F-319776C90880

Q34200875-2C680AC6-356F-413F-8642-8B010A8801AC

Q34200875-2FC517AB-536B-46F6-9684-234DAF4C6559

Q34200875-3B7E2CA4-D1E0-4282-94AF-A0BE6536C6CD

P304

Q34200875-83A5D3DB-7210-4699-923D-5C703D2FCECF

P31

Q34200875-FB658B80-AD65-4168-941F-14739280C85C

P356

Q34200875-4A47E464-9E64-4D94-9F6B-41515A9EA6EE

P407

Q34200875-BBBA4999-55E8-4576-93C9-E077226C0794

P433

Q34200875-76709D60-C034-4955-9E03-FDBEE977ACF3

P478

Q34200875-7D0EB65D-AAE8-4176-8D7A-6FE825035857

P577

Q34200875-FB868C67-04FD-4BF1-91DD-2A99EBAC5C8F

P5875

Q34200875-1EDAD120-CE9D-4F0F-9A2B-1457F66BC5C0

P698

Q34200875-0875520E-490A-4D32-8A68-FDEF8D5CC8FA

P932

Q34200875-21D19844-BD04-4FC1-8CE3-942E566387D9

P356

JOURNAL.PONE.0033379

P1433

P1476

Activation of PI3K/AKT and MAP ...... e in hepatocellular carcinoma.

@en

P2093

Ai-Wu Ke

http://www.w3.org/2001/XMLSchema#string

Chang-Jun Tan

http://www.w3.org/2001/XMLSchema#string

Fang-Ming Gu

http://www.w3.org/2001/XMLSchema#string

Jia Fan

http://www.w3.org/2001/XMLSchema#string

Jia-Hao Jiang

http://www.w3.org/2001/XMLSchema#string

Jian Zhou

http://www.w3.org/2001/XMLSchema#string

Li-Qing Yao

http://www.w3.org/2001/XMLSchema#string

Quan-Lin Li

http://www.w3.org/2001/XMLSchema#string

Xiao-Yong Huang

http://www.w3.org/2001/XMLSchema#string

Zheng Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

Cell signaling by receptor tyrosine kinases

Mechanisms of resistance to rapamycins

Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor

Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience

mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells.

P304

e33379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0033379

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221716449

http://www.w3.org/2001/XMLSchema#string

P698

22428038

http://www.w3.org/2001/XMLSchema#string

P932

3302853

http://www.w3.org/2001/XMLSchema#string